| |
Innovative immune therapy advancements don't just happen anywhere. Discover why the industry's leaders choose Puerto Rico to impact the world. It's not what's next, it's where.
|
|
Today’s Big NewsMar 25, 2024 |
| By Nick Paul Taylor Novo Nordisk is pumping up its heart failure plans. The drugmaker, dripping with its GLP-1 billions, has agreed to buy Cardior Pharmaceuticals and its midphase prospect in a deal that could top out above 1 billion euros ($1.1 billion). |
|
|
|
By Kevin Dunleavy Eli Lilly’s revenue is tracking upward, its share price has climbed and its market cap has skyrocketed to the highest in the biopharma industry. It's little wonder, then, that the company's executives are raking in the rewards. In 2023, Lilly CEO David Ricks received a 24% boost in overall compensation. |
By Conor Hale Masimo said it will form a new company to house its home audio brands plus its high-tech Stork baby monitor system and its line of health-focused smartwatches. |
By Ben Adams It’s March, so it’s time for some #FierceMadness. Last year, we channeled the NCAA tournament for the best pharma ad campaigns, but this year we’re looking for the best of the best in drug names. |
|
Monday, April 22, 2024 | 10am ET / 7am PT Explore cutting-edge NASH research with a novel NAFLD/NASH animal model mirroring patient experiences. Witness Resmetirom's impact on fat accumulation using human cell-based in vitro models. Expect clinical relevance, quick insights in 12-16 weeks, and cost savings. Register now!
|
|
By Annalee Armstrong,Max Bayer,Gabrielle Masson,James Waldron What's the best biotech name? It's time to vote in the Fierce Madness #biotechbracket. |
By Angus Liu Nearly five years after an FDA approval for Soliris in neuromyelitis optica spectrum disorder (NMOSD), AstraZeneca’s follow-on C5 drug Ultomiris has entered the rare neurological disease, as well. |
By James Waldron Regeneron may have gotten ahead of itself with the early filing of bispecific antibody odronextamab to regulators. In a move that might not surprise keen FDA watchers, the agency has issued two complete response letters over the timelines of ongoing phase 3 confirmatory trials for the drug. |
By Eric Sagonowsky Even as Germany's BioNTech deals with ongoing declines of its revenue and share price, it's facing another serious concern: U.S. officials are pressing the company to pay royalties linked to the commercialization of its lucrative Pfizer-partnered COVID-19 vaccine. |
By Nick Paul Taylor AstraZeneca is stepping back into Fasenra promotion to show how its asthma treatment can help people with asthma step back out. |
By Conor Hale The FDA last week re-upped its recommendations that healthcare providers avoid using plastic syringes made in China wherever possible, while it continues to investigate growing quality concerns. In response, BD said it would be increasing U.S. production of the ubiquitous drug delivery hardware to help cover the gap. |
By Fraiser Kansteiner After filing a challenge in November against more than 100 patents in the FDA’s Orange Book—and persuading several drugmakers to retract their intellectual property (IP) protections in the process—the U.S. Federal Trade Commission is now calling out uncooperative companies in court. |
By Annalee Armstrong AbbVie has grabbed a wrench to add on some new autoimmune disease options to its pipeline via the acquisition of Landos Biopharma. The deal values the oral therapeutic-focused biotech at $137.5 million. |
By Andrea Park SK Life Science is in a purple haze this week to help raise awareness around epilepsy. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we explore the European biotech investment landscape. Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. |
|
|---|
|
|
|
Thursday, April 11, 2024 | 11am ET / 8am PT As clinical trials increase in complexity, drug developers face growing pressure to deliver on-time, on-budget studies. FSP partnerships have emerged as a pivotal strategy to help address current challenges. Join us to learn moreas we explore the findings of The 2024 FSP Trends Report from the PPD clinical research business of Thermo Fisher Scientific. Sign up now!
|
|
| WhitepaperExplore the nuanced approaches necessary for successful pediatric drug development. Sponsored by: PPD |
| Whitepaper This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment. Presented by Blue Matter, strategic consultants in the life sciences |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
